Effects of pharmacological manipulation of dopaminergic and cholinergic neurotransmission in genetically dystonic hamsters.
In an inbred line of Syrian hamsters, attacks of sustained dystonic postures of the limbs and trunk can be initiated by handling or mild environmental stimuli (e.g. new cage). The severity of the dystonic syndrome in these mutant hamsters (gene symbol dtSZ) is age-dependent, with a peak at about 30-40 days of age. A scoring system for grading the type and severity of the dystonic attacks can be used to study the activity of drugs against dystonic movements with individual pre- and post-drug vehicle trials as control. The effects of drugs which alter dopaminergic or cholinergic functions in the brain were studied in selectively bred dystonic hamsters and age-matched non-dystonic controls. The dopamine precursor levodopa (injected together with carbidopa) and the dopamine receptor agonist apomorphine increased the severity of dystonia in hamsters when administered prior to the age of maximum severity of dystonia. A very similar effect was observed with the cholinomimetic pilocarpine. In contrast, the dopamine receptor antagonist haloperidol caused a marked overall reduction in dystonic movements. Anticholinergic drugs, i.e. trihexyphenidyl and biperiden, increased the latency to onset of the dystonic attack, but did not reduce its severity. No differences were observed between dystonic and non-dystonic hamsters with respect to extent and duration of stereotypies induced by dopaminergic and cholinergic drugs or hypolocomotion and catalepsy produced by haloperidol. The data suggest that dopaminergic hyperactivity might be involved in the pathophysiology of dystonia in dtSZ mutant hamsters.
Löscher
W
W
Department of Pharmacology, Toxicology and Pharmacy, School of Veterinary Medicine, Hannover, F.R.G.
Fredow
G
G
D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D001058:Apomorphine / Q000008:administration & dosage / Q000494:pharmacology; D001522:Behavior, Animal; D002230:Carbidopa / Q000494:pharmacology; D006224:Cricetinae; D004298:Dopamine / Q000378:metabolism*; D004347:Drug Interactions; D004421:Dystonia / Q000235:genetics / Q000503:physiopathology*; D006220:Haloperidol / Q000008:administration & dosage / Q000494:pharmacology; D007980:Levodopa / Q000494:pharmacology; D008647:Mesocricetus; D009043:Motor Activity / Q000187:drug effects*; D009154:Mutation; D010862:Pilocarpine / Q000494:pharmacology; D009435:Synaptic Transmission / Q000187:drug effects*; D014282:Trihexyphenidyl / Q000494:pharmacology
D010862:Pilocarpine; D007980:Levodopa; D014282:Trihexyphenidyl; D006220:Haloperidol; D002230:Carbidopa; D001058:Apomorphine; D000109:Acetylcholine; D004298:Dopamine